alexa Successful anti-hepatitis C virus therapy with telaprevir in an HIV hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Antonini TM, Furlan V, Teicher E, HaimBoukobza S, Sebagh M, , Antonini TM, Furlan V, Teicher E, HaimBoukobza S, Sebagh M,

Abstract Share this page

Abstract We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed. This article was published in AIDS and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords